MRM

MEDIROM Healthcare Technologies
MRM
Market cap $14M

2.84 USD

+0.09

3.27%

Updated Nov 19, 11:54 AM EST

1 day

3.27%

5 days

7.17%

1 month

-8.09%

3 months

3.65%

6 months

-51.12%

Year to date

-50.52%

1 year

-41.80%

5 years

-81.20%

10 years

-81.20%

About: MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.

Employees: 1,101

0

Funds holding %

of 6,735 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

24,986% more capital invested

Capital invested by funds: $216 [Q2] → $54.2K (+$54K) [Q3]

0.37% more ownership

Funds ownership: 0% [Q2] → 0.37% (+0.37%) [Q3]

0% more funds holding

Funds holding: 2 [Q2] → 2 (+0) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for MRM.

See Analyst Rankings

Financial journalist opinion

SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance

TOKYO--(BUSINESS WIRE)-- #InvestorRelations--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) , announced a business alliance with MEDIROM Healthcare Technologies Inc.(Nasdaq: MRM) .

SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance

MEDIROM Rehab Solutions Inc. Acquires Rehabilitation Centers from Y's, Inc.

TOKYO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“Medirom” or the “Company”) is pleased to announce that it is capitalizing on its extensive experience operating wellness clinics and healthcare technology to expand into the rehabilitation industry. In doing so, MEDIROM established a wholly-owned subsidiary, MEDIROM Rehab Solutions Inc., which acquired all of the rehabilitation centers of Y's, Inc. Prior to the acquisition by MEDIROM Rehab Solutions Inc., Y's, Inc. owned and operated ten cerebral infarction rehabilitation centers in Tokyo and other major cities across Japan.

MEDIROM Rehab Solutions Inc. Acquires Rehabilitation Centers from Y's, Inc.

Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies

NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen

Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies

MEDIROM Healthcare Technologies Announces Business Transfer from Y's, Inc.

TOKYO, July 22, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (“we”, “our”, “us” or “the Company”) hereby announces that its subsidiary MEDIROM Rehab Solutions Inc. entered into an agreement to purchase a rehabilitation business from Y's, Inc., a Japanese corporation, as of July 10, 2024.

MEDIROM Healthcare Technologies Announces Business Transfer from Y's, Inc.

MEDIROM Healthcare Technologies Announces Acquisition of Japan Gene Medicine Corporation

NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (“we”, “our”, “us” or “the Company”) hereby announces that the Company plans to acquire a majority of Japan Gene Medicine Corporation (the “Target Company”). On June 30, 2024, the Company entered into a share transfer agreement (the "Share Transfer Agreement") to acquire 70.0% of the shares of the Target Company from an individual shareholder. The Company has also entered into a legally binding memorandum of understanding (the "Additional Transfer Memorandum of Understanding"), effective as of June 30, 2024, to obtain an option to acquire the remaining 30.0% of the Target Company's shares from the seller. The closings of the transactions under the Share Transfer Agreement and Additional Transfer Memorandum of Understanding are each subject to certain conditions. Certain of these closing conditions under the Share Transfer Agreement are summarized below.

MEDIROM Healthcare Technologies Announces Acquisition of Japan Gene Medicine Corporation

The first JAPAN IR Event 2024 was held at Nasdaq's U.S. headquarters

Four Nasdaq-listed Japanese Companies Gather to Showcase the Appeal of Japanese Companies to the World Four Nasdaq-listed Japanese Companies Gather to Showcase the Appeal of Japanese Companies to the World

The first JAPAN IR Event 2024 was held at Nasdaq's U.S. headquarters

MEDIROM Healthcare Technologies Inc. Announces Financial Results for Fiscal Year 2023

TOKYO, June 25, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“Medirom” or the “Company”), a holistic healthcare company based in Japan, announced it filed its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC"), including consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), on June 18, 2024.

MEDIROM Healthcare Technologies Inc. Announces Financial Results for Fiscal Year 2023

“NASDAQ JAPAN IR EVENT” to Be Held at Nasdaq MarketSite on June 20, 2024

NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM”, the “Company”), today announced it will participate in a “NASDAQ JAPAN IR EVENT” to be held at Nasdaq MarketSite in Times Square on June 20, 2024. Five companies are currently expected to join this event (including one private company), and we will share information about the attractive nature of the Japanese market with a global audience.

“NASDAQ JAPAN IR EVENT” to Be Held at Nasdaq MarketSite on June 20, 2024

MEDIROM Healthcare Technologies Inc. Announces March 2024 Key Performance Indicators (KPIs)

TOKYO, April 25, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, updated for the month of March 2024. Data is provided for all salons for which comparative financial and customer data is available and excludes certain salons where such information is not available.

MEDIROM Healthcare Technologies Inc. Announces March 2024 Key Performance Indicators (KPIs)

Announcement Execution of Memorandum of Understanding for Share Acquisition (Subsidiarization)

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (“we”, “our” or “us”) hereby announces that we resolved, at a meeting of our Board of Directors held on March 29, 2024, to enter into a Memorandum of Understanding (the “MOU”) for the purpose of acquiring all of the shares of stock of Japan Gene Medicine Corporation (the “Target Company”) and making it our subsidiary, and commencing the processes and negotiations necessary to enter into the definitive agreement for the transaction. The MOU was executed on April 2, 2024.

Announcement Execution of Memorandum of Understanding for Share Acquisition (Subsidiarization)

See News Rankings

Charts implemented using Lightweight Charts™